Related Experiment Video
Updated: May 26, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Association between ATM polymorphisms and cancer risk: a meta-analysis
Li Shen1, Zhi-Hua Yin, Yan Wan
1Department of Epidemiology, School of Public Health, China Medical University, Shenyang, 110001, China.
Molecular Biology Reports
|December 29, 2011
Summary
This meta-analysis found that Ataxia-telangiectasia mutated (ATM) gene polymorphisms, specifically rs664143, are associated with increased cancer risk. The rs664143 variant showed a significant link to lung cancer susceptibility, particularly in Asian populations.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Epidemiological studies have explored the link between Ataxia-telangiectasia mutated (ATM) gene polymorphisms and various cancer risks, but findings remain inconsistent.
- Contradictory results necessitate further investigation into specific ATM single nucleotide polymorphisms (SNPs) and their association with cancer susceptibility.
Purpose of the Study:
- To conduct a meta-analysis evaluating the association between two ATM gene SNPs (rs664143 and rs664677) and overall cancer risk.
- To investigate the relationship between these specific ATM SNPs and the risk of lung, breast, glioma, and pancreatic cancers.
Main Methods:
- A meta-analysis of published case-control studies was performed.
- Data from 12 publications were synthesized, focusing on 8 studies for rs664143 and 7 for rs664677.
- Subgroup analyses were conducted based on cancer type and geographic region.
Main Results:
- The ATM rs664143 polymorphism was associated with an overall increased cancer risk, particularly in heterozygote carriers (OR=1.18, 95% CI 1.02-1.36).
- Significant associations were found between ATM rs664143 and increased lung cancer risk (GA vs. GG: OR=1.48, AA vs. GG: OR=1.51).
- ATM rs664677 was linked to decreased lung cancer risk (TC vs. TT: OR=0.76, CC vs. TT: OR=0.80) and increased breast cancer risk (TC vs. TT: OR=1.42, CC vs. TT: OR=1.51).
- In Asian populations, ATM rs664143 (GA or AA genotypes) showed a clear increase in cancer risk (GA vs. GG: OR=1.40, AA vs. GG: OR=1.37).
Conclusions:
- The ATM rs664143 polymorphism is associated with cancer susceptibility.
- ATM rs664143 is significantly linked to an elevated risk of developing lung cancer.
- ATM rs664677 demonstrates a dual role, associated with reduced lung cancer risk and increased breast cancer risk.
Related Concept Videos
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...